Guide to Implementation Table 9: Guide to Implementation for Pharmaceutical measures Measures Preparedness Standby Initial Action Targeted Action: Targeted Targeted Action: Standdown Practicalities Low CS Action: High CS Moderate CS Used for As for Treat cases if Move away from Delivery Delivery capacity Cases as Use for all cases Antivirals: treatment seasonal seasonal appropriate treating mild capacity will will become an issue required by Effectiveness strongly influenza influenza cases to become an issue condition dependent on timely protecting those at delivery and compliance. risk of severe Risk of stockpile outcomes depletion with widespread distribution. close contacts, contacts at risk of close contacts & close contacts, Antivirals: post-exposure possible at risk severe illness healthcare contacts at high risk prophylaxis contacts, workers of severe illness, healthcare increasingly as healthcare workers workers cs rises, (depending on contacts at risk exposure risk) of severe illness Delivery capacity will become an issue Antivirals: HCW (depending on exposure risk) pre-exposure prophylaxis Candidate If vaccine proves to Unlikely to offer full vaccine be effective. protection. Useful if pandemic strain and candidate are same subtype. Possible adverse events. At risk Not initially available. Customised pandemic groups Access is a key goal of vaccine the response
Guide to Implementation Table 9: Guide to Implementation for Pharmaceutical measures Measures Preparedness Standby Initial Action Targeted Action: Low CS Targeted Action: Moderate CS Targeted Action: High CS Standdown Practicalities Antivirals: treatment Used for seasonal influenza As for seasonal influenza Treat cases if appropriate Move away from treating mild cases to protecting those at risk of severe outcomes Delivery capacity will become an issue Delivery capacity will become an issue Cases as required by condition Use for all cases Effectiveness strongly dependent on timely delivery and compliance. Risk of stockpile depletion with widespread distribution. Antivirals: post-exposure prophylaxis close contacts, possible at risk contacts, healthcare workers contacts at risk of severe illness close contacts & healthcare workers increasingly as cs rises, contacts at risk of severe illness close contacts, contacts at high risk of severe illness, healthcare workers (depending on exposure risk) Delivery capacity will become an issue Antivirals: pre-exposure prophylaxis HCW (depending on exposure risk) Candidate vaccine If vaccine proves to be effective. Unlikely to offer full protection. Useful if pandemic strain and candidate are same subtype. Possible adverse events. Customised pandemic vaccine At risk groups Not initially available. Access is a key goal of the response
w-AHMPPI.docx